Press Releases

The following are official statements issued by UsAgainstAlzheimer’s in response to major national policy actions, industry events, breaking news, or organizational achievements. Please see the UsAgainstAlzheimer’s press kit page for additional information. For media requests, please contact Jon Summers at jsummers@usagainstalzheimers.org.

  • March 13, 2023

    Veterans Affairs Decision to Cover Leqembi Should Serve as Model for Federal Regulators

    UsAgainstAlzheimer’s chair and co-founder George Vradenburg issued the following statement in response...

    Read more
  • February 27, 2023

    Statement on the Retirement of Dr. Billy Dunn

    UsAgainstAlzheimer’s chair and co-founder George Vradenburg issued the following statement regarding the...

    Read more
  • February 23, 2023

    CMS Slams the Door on Alzheimer’s Patients – Again

    UsAgainstAlzheimer’s chair and co-founder George Vradenburg issued the following statement in response...

    Read more
  • January 31, 2023

    Senator Collins, Bipartisan Colleagues Introduce Bills to Bolster Alzheimer’s Research

    Senators Susan Collins (R-ME), Mark Warner (D-VA), Shelley Moore Capito...

    Read more
  • January 20, 2023

    UsAgainstAlzheimer’s Statement on FDA Complete Response Letter for Donanemab

    Washington, D.C. (January 19, 2023) – UsAgainstAlzheimer’s chief operating officer Russ Paulsen issued...

    Read more
  • January 06, 2023

    Alzheimer's Patients and Caregivers Celebrate FDA Approval of Lecanemab

    Washington, D.C. (January 6, 2022) – Millions of Americans living with Alzheimer’s...

    Read more
  • December 23, 2022

    Congress Delivers Major Wins for Alzheimer’s Patients

     Alzheimer’s patients, caregivers, and advocates secured major wins in the end-of-year budget...

    Read more
  • December 01, 2022

    Gantenerumab Trial Results Reinforce Need for Continued Research and Treatment-Specific Regulation

    Yesterday, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, researchers ...

    Read more
  • November 30, 2022

    Lecanemab Trial Data Gives Hope to Alzheimer’s Community

    Washington, DC (November 29, 2022) – Promising new data released today...

    Read more

Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer's. This report found that deep social inequities exist in countries highly impacted by Alzheimer's among Latinos and Blacks.

Read Report